tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

= Pharming Group NV ADS trading resumes
The Fly= Pharming Group NV ADS trading resumes
6d ago
PHAR
= Pharming Group NV ADS trading halted, volatility trading pause
PremiumThe Fly
= Pharming Group NV ADS trading halted, volatility trading pause
6d ago
PHAR
Pharming price target raised to EUR 2.45 from EUR 2 at RBC Capital
PremiumThe Fly
Pharming price target raised to EUR 2.45 from EUR 2 at RBC Capital
8d ago
PHAR
Pharming Group N.V. Reports Strong Q2 Earnings
PremiumCompany Announcements
Pharming Group N.V. Reports Strong Q2 Earnings
13d ago
Pharming price target raised to $41 from $40 at Oppenheimer
PremiumThe Fly
Pharming price target raised to $41 from $40 at Oppenheimer
13d ago
PHAR
Pharming Group’s Strong Financial Performance and Strategic Developments Justify Buy Rating
PremiumRatingsPharming Group’s Strong Financial Performance and Strategic Developments Justify Buy Rating
13d ago
PHAR
Pharming Group Reports Strong Revenue Growth in 2025
Premium
Company Announcements
Pharming Group Reports Strong Revenue Growth in 2025
14d ago
Pharming Group’s Growth Potential Boosted by Advances in APDS Diagnosis and Treatment
Premium
Ratings
Pharming Group’s Growth Potential Boosted by Advances in APDS Diagnosis and Treatment
2M ago
PHAR
Pharming management to meet with Oppenheimer
PremiumThe Fly
Pharming management to meet with Oppenheimer
3M ago
PHAR
Pharming Group N.V. Reports Strong Q1 2025 Earnings
PremiumCompany Announcements
Pharming Group N.V. Reports Strong Q1 2025 Earnings
3M ago
Pharming Group Reports Strong Q1 2025 Growth
PremiumCompany Announcements
Pharming Group Reports Strong Q1 2025 Growth
3M ago
Pharming Group’s Strong Financial Performance and Strategic Growth Drive Buy Rating
PremiumRatings
Pharming Group’s Strong Financial Performance and Strategic Growth Drive Buy Rating
3M ago
PHAR
PHGUF Earnings this Week: How Will it Perform?
PremiumPre-EarningsPHGUF Earnings this Week: How Will it Perform?
3M ago
Pharming announces positive recommendation from NICE for Joenja
Premium
The Fly
Pharming announces positive recommendation from NICE for Joenja
4M ago
PHAR
Pharming Group’s Strategic Expansion and NICE Endorsement Drive Buy Rating
Premium
Ratings
Pharming Group’s Strategic Expansion and NICE Endorsement Drive Buy Rating
4M ago
PHAR
Pharming price target lowered to EUR 2 from EUR 2.15 at RBC Capital
PremiumThe Fly
Pharming price target lowered to EUR 2 from EUR 2.15 at RBC Capital
4M ago
PHAR
Pharming Group to Engage Investors at April Conferences
PremiumCompany Announcements
Pharming Group to Engage Investors at April Conferences
5M ago
Pharming Group Begins Phase II Trial for CVID Treatment
PremiumCompany Announcements
Pharming Group Begins Phase II Trial for CVID Treatment
5M ago
Pharming Group’s Earnings Call Highlights Robust Growth
PremiumCompany Announcements
Pharming Group’s Earnings Call Highlights Robust Growth
5M ago
Pharming price target raised to $39 from $30 at Oppenheimer
PremiumThe FlyPharming price target raised to $39 from $30 at Oppenheimer
5M ago
PHAR
Pharming Group’s Strong Financial Performance and Strategic Initiatives Justify Buy Rating
Premium
Ratings
Pharming Group’s Strong Financial Performance and Strategic Initiatives Justify Buy Rating
5M ago
PHAR
Pharming Group Reports Strong Revenue Growth for 2024
Premium
Company Announcements
Pharming Group Reports Strong Revenue Growth for 2024
5M ago

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >